Ardena appoints Ariane de Ganck as Chief Scientific Officer

Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022

Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO, has appointed Ariane de Ganck as Chief Scientific Officer (CSO)

Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022 and her recent role as Chief Commercial Officer. 

Since joining Ardena in 2019, she has overseen the company’s drug product operations, led the successful acquisition and integration of the Ardena Pamplona site, and supported the expansion of Ardena’s development capabilities into aseptic fill and finish services.

As Chief Scientific Officer, Ariane will lead three key areas: Science & Technology, Project Management and CMC Regulatory Affairs. Through Science & Technology, she will advance scientific exchange across Ardena and with external industry experts and thought leaders, ensuring scientific knowledge and expertise are shared effectively across disciplines and sites. 

“Ariane’s track record across scientific, operational and commercial leadership roles makes her exceptionally well suited to this position,” said Jeremie Trochu, CEO of Ardena. 

Ariane holds a PhD in Biomedical Sciences, with a specialty in oncology and protein biology. Her research centered on understanding proteins driving cancer cell migration and invasion.

“Scientific expertise is the foundation of how Ardena supports complex drug development, from drug substance and drug product through to bioanalysis, nanomedicines, solid-state chemistry and CMC regulatory services,” said Ariane de Ganck, Chief Scientific Officer at Ardena.